Everybody is aware of the outbreak of the deadly COVID-19 virus. COVID‐19 cutaneous manifestations have been recently described and classified in five different clinical patterns, including acral erythema‐edema (pseudo‐chilblain), maculopapular exanthemas, vesicular eruptions, urticarial lesions, and livedo or necrosis. The study’s main objective was to examine the skin of hospitalized patients with a confirmed diagnosis of COVID‐19 disease and describe the real prevalence of skin manifestations. The researchers performed a cross‐sectional study that included hospitalized patients in Cruces University Hospital from April 14–30, 2020, with a laboratory‐confirmed diagnosis of COVID‐19. Experienced dermatologists performed entire body surface examinations to search for cutaneous manifestations related to COVID‐19 disease.
As a result, among 75 patients, 14 (18.7%) developed cutaneous manifestations related to COVID‐19. We found six patients with acral erythema‐edema (pseudo‐chilblain) (42.8%), four patients with maculopapular exanthemas (28.6%), two patients with urticarial lesions (14.3%), one patient with livedo reticularis‐like lesions (7.15%), and one patient with vesicular eruption (7.15%). Our study provides a more plausible relationship between the main cutaneous patterns and COVID‐19 in hospitalized patients, as all of them had a confirmatory laboratory test. Skin manifestations are frequent but mild with spontaneous resolution. These findings are nonspecific and can be similar to other viral infections and adverse drug reactions in hospitalized patients.